Park Square Financial Group’s AstraZeneca AZN Stock Holding History

Park Square Financial Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.6K	Buy	+59	New	+$11.4K	0.09%	73
2025 Q4	–	Sell	-159	Closed	-$24.4K	–	245
2025 Q3	$24.4K	Buy	159 +35	+28%	+$5.3K	0.11%	75
2025 Q2	$17.3K	Buy	124 +50	+68%	+$7.01K	0.01%	496
2025 Q1	$10.8K	Buy	74 +51	+222%	+$7.38K	0.01%	578
2024 Q4	$3.01K	Buy	+23	New	+$3.22K	﹤0.01%	779

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Park Square Financial Group's AZN Position: Q1 2026 in Review

Park Square Financial Group opened a new position in AstraZeneca (AZN) in Q1 2026: 59 shares worth $11.6K. The stake represents 0.09% of the portfolio and ranks #73 among its holdings. This is a return to the name: Park Square Financial Group previously reported a position in AZN as recently as Q3 2025.

Park Square Financial Group first reported a position in AZN in Q4 2024 and has held it in 5 quarters since. The position peaked at $24.4K in Q3 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Park Square Financial Group held 59 shares of AstraZeneca worth $11.6K as of Q1 2026.
AstraZeneca was a new Park Square Financial Group position in Q1 2026.
AstraZeneca made up 0.09% of Park Square Financial Group's portfolio in Q1 2026, its #73 holding.
Park Square Financial Group first reported a position in AstraZeneca in Q4 2024 and has held it in 5 quarters since.
Park Square Financial Group's AstraZeneca position peaked at $24.4K in Q3 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Park Square Financial Group's 13F filing for Q1 2026, filed 13 May 2026.